REGENXBIO

Traded on the St. Petersburg Stock Exchange Add to favourites
REGENXBIO is a biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.
REGENXBIO stock price chart
vol.
change
Created with Highcharts 8.2.230. Jul1. Aug5. Aug7. Aug13. Aug15. Aug19. Aug21. Aug23. Aug26. Jul9. Aug201620172018201920202021202220232024$11$12$13$14$15$16Zoom1w1m3m6m1yAllYTDFromMay 23, 2024ToAug 23, 2024RGNXNewsDividends
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

REGENXBIO balance sheet

Report period2018 Download reports for the period: 2018 2019 Download reports for the period: 2019 2020 Download reports for the period: 2020 2021 Download reports for the period: 2021 2022 Download reports for the period: 2022 Q3 23 Download reports for the period: Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

REGENXBIO cash flows

Report period2018 Download reports for the period: 2018 2019 Download reports for the period: 2019 2020 Download reports for the period: 2020 2021 Download reports for the period: 2021 2022 Download reports for the period: 2022 Q3 23 TTM Download reports for the period: Q3 23
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

REGENXBIO multipliers

REGENXBIO profitability

REGENXBIO assets
Created with Highcharts 8.2.2Assets, million $Liabilities/Assets, %Access restrictedBook ValueLiabilitiesNet debtL/A
REGENXBIO cash flows
Created with Highcharts 8.2.2Access restrictedEarningsSalesFree Cash FlowOperation IncomeEBITDA

REGENXBIO shares

TickerNameTypeNominal valueISINPrice
RGNX:USREGENXBIO, Inc.Common share-US75901B1070$12.13
REGENXBIO news
05.05.2022
REGENXBIO's GAAP loss for 3 months of 2022 was $76.723 million, up 53% from $50.139 million in the prior year. Revenue increased 17.7% to $22.218 million from $18.884 million a year earlier.
Source: {source} pictogram ir.regenxbio.com
Pictogram next
02.03.2022
Net income of REGENXBIO under GAAP for 2021 was $127.84 million, compared to a loss of $111.25 million in the previous year. Revenue tripled to $470.347 million from $154.567 million a year earlier.
Source: {source} pictogram regenxbio.gcs-web.com
Pictogram next
03.11.2021
REGENXBIO posted a GAAP loss of $166.183 million for 9M 2021, up 2.6 times from $65.009 million in the previous year. Revenues decreased by 46.1% to $71.692 million from $133.122 million a year earlier.
Source: {source} pictogram regenxbio.gcs-web.com
Pictogram next
10.08.2021
REGENXBIO's GAAP loss for 6M 2021 was $107.778 million, up 46% from $73.8 million in the previous year. Revenue increased 19.6% to $40.919 million from $34.21 million a year earlier.
Source: {source} pictogram regenxbio.gcs-web.com
Pictogram next
All REGENXBIO news
General information
Company nameREGENXBIO
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address9600 BLACKWELL ROAD SUITE 210 ROCKVILLE MD 20850 240-552-8181
Mailing address9600 BLACKWELL ROAD SUITE 210 ROCKVILLE MD 20850
Websitewww.regenxbio.com
Information disclosurewww.sec.gov